The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]
The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]
Panelists discuss how a 54-year-old woman with early-onset Parkinson disease presenting with troublesome peak-dose dyskinesia affecting her work performance illustrates the challenge of managing patients who have both dyskinesia and likely OFF episodes, requiring careful assessment of functional impacts through targeted questioning about daily activities, work performance, and social interactions, since patients often minimize or remain unaware of their dyskinesia's true impact while caregivers may provide crucial insights into how the involuntary movements affect not only the patient but also family dynamics and professional relationships.
A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigational therapy. [WATCH TIME: 7 minutes]
Panelists discuss how dyskinesia affects 30% to 50% of Parkinson patients by 5 years and over 90% by 10 years, creating significant functional limitations including impaired writing, eating, and dressing abilities, increased fall risk, job performance challenges, social isolation due to embarrassment about abnormal movements, and restrictions on therapeutic options since increasing levodopa doses to manage OFF time would worsen dyskinesia, ultimately impacting both patients' basic human dignity and their caregivers' quality of life.
The professor of neurology at Thomas Jefferson University discussed the shifting diagnostic challenges of stiff person syndrome and reviewed current and emerging treatment options. [WATCH TIME: 6 minutes]
The associate professor of neurology at Johns Hopkins detailed how artificial intelligence is shaping the future of neurology through its integration in clinical care, research, and medical education. [WATCH TIME: 4 minutes]
Neurology News Network. for the week ending July 19, 2025. [WATCH TIME: 4 minutes]
At AHS 2025, the assistant professor of neurology at the Icahn School of Medicine at Mount Sinai highlighted the challenges LGBTQIA+ individuals may face in migraine care. [WATCH TIME: 6 minutes]
The assistant professor of neurology at Wake Forest Baptist Atrium Health discussed emerging research on how breast size may contribute to headache disorders, including migraine. [WATCH TIME: 5 minutes]
A panelist discusses the use of dual orexin receptor antagonists as a first-line treatment for chronic insomnia due to their efficacy in improving sleep without the risks of dependence or cognitive issues, while also noting their effectiveness in patients with psychophysiologic insomnia and the importance of managing patient expectations regarding their use.
The professor of neurology at the University of Miami Miller School of Medicine provided context on the clinical use of the Cognivue Amyloid Risk Measure in the context of Alzheimer disease care. [WATCH TIME: 3 minutes]
The professor of neuroscience at Harvard Medical School highlighted gaps in headache care access, provider training, and medication availability in regions like Kenya and the Philippines. [WATCH TIME: 5 minutes]
The director of sleep health at Flinders University in Australia explored how combination pharmacologic and noninvasive therapies may offer a personalized path forward in obstructive sleep apnea treatment. [WATCH TIME: 6 minutes]
Nuri Jacoby, MD, a neurologist at Maimonides Medical Center and SUNY Downstate, previewed his talk at the 2025 AUPN Annual Meeting on using simulation to evaluate nonclinical competencies like communication and professionalism. [WATCH TIME: 3 minutes]
The professor of neurological surgery at Weill Cornell Medicine shared his reaction to the recent approval of the Exablate Neuro platform that uses MRI-guided focused ultrasound to treat Parkinson disease. [WATCH TIME: 5 minutes]
The associate professor of medicine at the Icahn School of Medicine at Mount Sinai outlined emerging interventions aimed at enhancing glymphatic clearance to potentially lower Alzheimer disease risk. [WATCH TIME: 4 minutes]
Panelists discuss how newer Parkinson disease therapies may impact dyskinesia management by potentially providing continuous dopaminergic stimulation that could prevent dyskinesia development if used early, though current evidence from phase 3 trials shows mixed results with improvements in good ON time (ON time without troublesome dyskinesia) but limited reduction in existing troublesome dyskinesia, suggesting that while these treatments offer promise, more research is needed to determine their effectiveness in reducing dyskinesia in patients who already experience it.
Panelists discuss how recent advancements in Parkinson disease treatment include 3 newly approved medications—an oral extended-release carbidopa-levodopa with mucoadhesive properties, a subcutaneous foslevodopa infusion, and a subcutaneous apomorphine infusion—that aim to provide more continuous dopamine stimulation and reduce motor fluctuations by offering longer-lasting benefits and smoother symptom control compared with traditional immediate-release formulations.
The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]
The professor of neurology at Albert Einstein College of Medicine talked about new findings presented at AHS, which suggested that both men and women with migraine can face significantly increased risks of ischemic stroke. [WATCH TIME: 5 minutes]
The director of the MedStar Georgetown Headache Center detailed how creative and comparative clinical trials can drive treatment personalization and strengthen clinical confidence. [WATCH: 4 minutes]
Neurology News Network. for the week ending July 12, 2025. [WATCH TIME: 4 minutes]
The professor of psychology at the University of Tulsa discussed the clinical utility of using CBT to treat nightmares–especially in children with comorbid conditions like ADHD and anxiety–and the latest research her lab is conducting. [WATCH TIME: 4 minutes]
The associate professor of neurology at Mayo Clinic College of Medicine discussed findings presented at AHS 2025 from a post hoc analysis of the phase 3b DELIVER study testing eptinezumab in patients with migraine. [WATCH TIME: 5 minutes]
A panelist discusses the strong efficacy and tolerability of dual orexin receptor antagonists (DORAs) for insomnia, noting their minimal adverse effects compared with older medications like benzodiazepines. DORAs are now seen as a first-line treatment option due to their favorable balance of safety and effectiveness, although insurance coverage can influence their availability.
The neuropsychiatry researcher at King's College London highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. [WATCH TIME: 5 minutes]
The assistant professor of medicine at Stanford University highlighted how gastrointestinal dysfunction in Parkinson disease can affect levodopa bioavailability and symptom management. [WATCH TIME: 7 minutes]
The associate professor of psychiatry and human behavior at UC Irvine explored how analyzing specific sleep oscillations may uncover early neurodegenerative changes and guide future therapeutic targets. [WATCH TIME: 4 minutes]
The director of movement disorders at the Banner Sun Health Research Institute discussed distinguishing atypical Parkinsonian disorders early and planning care around their complex symptomatology. [WATCH TIME: 4 minutes]
